• 1
    Smith RA, Mettlin CJ, Davis KJ, Eyre H. American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin 2000; 50: 3449.
  • 2
    Fink D. Guidelines for the cancer-related checkup. Atlanta, American Cancer Society, 1991.
  • 3
    Byers T, Levin B, Rothenberger D, et al. American Cancer Society guidelines for screening and surveillance for early detection of colorectal polyps and cancer: update 1997. CA Cancer J Clin 1997; 47: 154160.
  • 4
    Leitch AM, Dodd GD, Costanza M, et al. American Cancer Society guidelines for the early detection of breast cancer: update 1997. CA Cancer J Clin 1997; 47: 150153.
  • 5
    Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001; 51: 1536.
  • 6
    Ries L, Eisner M, Kosary C, et al. SEER Cancer Statistics Review, 1973–1997. Bethesda, MD: National Cancer Institute; 2000.
  • 7
    Stanford JL, Stephenson RA, Coyle LM, et al. Prostate Cancer Trends 1973–1995, SEER Program, National Cancer Institute. NIH Pub. No. 99–4543. Bethesda, MD, 1999.
  • 8
    Mettlin C, Jones G, Averette H, et al. Defining and updating the American Cancer Society guidelines for the cancer-related checkup: prostate and endometrial cancers. CA Cancer J Clin 1993; 43: 4246.
  • 9
    von Eschenbach A, Ho R, Murphy GP, et al. N. American Cancer Society guideline for the early detection of prostate cancer: update 1997. CA Cancer J Clin 1997; 47: 261264.
  • 10
    Reissigl A, Horninger W, Fink K, et al. Prostate carcinoma screening in the county of Tyrol, Austria: experience and results. Cancer 1997; 80: 18181829.
  • 11
    Bartsch G, Horninger W, Klocker H, et al. Decrease in prostate cancer mortality following introduction of prostate specific antigen (PSA) screening in the federal state of Tyrol, Austria. Annual Meeting of the American Urological Association; Atlanta;2000. (Abstract).
  • 12
    Tarone RE, Chu KC, Brawley OW. Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology 2000; 11: 167170.
  • 13
    Kramer BS, Gohagan J, Prorok PC, Smart C. A National Cancer Institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers. Cancer 1993; 71: 589593.
  • 14
    Gann PH. Interpreting recent trends in prostate cancer incidence and mortality. Epidemiology 1997; 8: 117120.
  • 15
    Roberts RO, Bergstralh EJ, Katusic SK, et al. Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota. J Urol 1999; 161: 529533.
  • 16
    Paquette E, Sun L, Paquette L, et al. The changing face of prostate cancer: evidence for the effectiveness of prostate cancer screening (manuscript in review).
  • 17
    Burack RC, Wood DP, Jr. Screening for prostate cancer. The challenge of promoting informed decision making in the absence of definitive evidence of effectiveness. Med Clin North Am1999; 83: 14231442, vi.
  • 18
    Chan EC, Sulmasy DP. What should men know about prostate-specific antigen screening before giving informed consent? Am J Med 1998; 105: 266274.
  • 19
    Wolf AM, Nasser JF, Schorling JB. The impact of informed consent on patient interest in prostate-specific antigen screening. Arch Intern Med 1996; 156: 13331336.
  • 20
    Wolf AM, Philbrick JT, Schorling JB. Predictors of interest in prostate-specific antigen screening and the impact of informed consent: what should we tell our patients? 1997; 103: 308314.
  • 21
    O'Dell KJ, Volk RJ, Cass AR, Spann SJ. Screening for prostate cancer with the prostate-specific antigen test: are patients making informed decisions? J Fam Pract 1999; 48: 682688.
  • 22
    Rodriguez C, Calle EE, Miracle-McMahill HL, et al. Family history and risk of fatal prostate cancer. Epidemiology 1997; 8: 653657.
  • 23
    Eyre HJ, Feldman GE. Status report on prostate cancer in African Americans: a national blueprint for action. CA Cancer J Clin 1998; 48: 315319.
  • 24
    DevCan: Probability of developing or dying of cancer (software), version 4. FeuerEJ, WunLM, Bethesda, MD, National Cancer Institute, 1999.
  • 25
    Winawer S, Zauber A, Ho M, et al. Prevention of colorectal cancer by colonoscopic polypectomy: The National Polyp Study Workgroup. N Engl J Med 1993; 331: 19771981.
  • 26
    Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: clinical guidelines and rationale [published errata appear in Gastroenterology 1997 Mar;112:1060 and 1998 Mar;114:625]. Gastroenterology 1997; 112: 594642.
  • 27
    Eddy D. ACS report on the cancer-related health checkup. CA Cancer J Clin 1980; 30: 193240.
  • 28
    Yamamoto M, Nakama H. Cost-effectiveness analysis of immunochemical occult blood screening for colorectal cancer among three fecal sampling methods. Hepatogastroenterology 2000; 47: 396399.
  • 29
    Ransohoff DF, Lang CA. Screening for colorectal cancer with the fecal occult blood test: a background paper. American College of Physicians. Ann Intern Med 1997; 126: 811822.
  • 30
    Lieberman DA, Weiss DG, Bond JH, et al. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med 2000; 343: 162168.
  • 31
    Rex DK, Johnson DA, Lieberman DA, Burt RW. Colorectal cancer prevention 2000: screening recommendations of the American College of Gastroenterology. American College of Gastroenterology. Am J Gastroenterol 2000; 95: 868877.
  • 32
    Glick S, Wagner JL, Johnson CD. Cost-effectiveness of double-contrast barium enema in screening for colorectal cancer. AJR Am J Roentgenol 1998; 170: 629636.
  • 33
    Halligan S, Fenlon HM. Virtual colonoscopy. BMJ 1999; 319: 12491252.
  • 34
    Jen J, Johnson C, Levin B. Molecular approaches for colorectal cancer screening. Eur J Gastroenterol Hepatol 1998; 10: 213217.
  • 35
    Ahlquist DA, Skoletsky JE, Boynton KA, et al. Colorectal cancer screening by detection of altered human DNA in stool: Feasibility of a multitarget assay panel. Gastroenterology 2000; 119: 12191227.
  • 36
    Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87: 159170.
  • 37
    Kronborg O, Fenger C. Clinical evidence for the adenoma-carcinoma sequence. Eur J Cancer Prev 1999; 8 Suppl 1: S73S86.
  • 38
    Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study [published erratum appears in N Engl J Med 1993 Aug 26;329:672] N Engl J Med1993; 13651371.
  • 39
    Selby JV, Friedman GD, Quesenberry CPJ, Weiss NS. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 1992; 326: 653657.
  • 40
    Newcomb PA, Norfleet RG, Storer BE, et al. Screening sigmoidoscopy and colorectal cancer mortality. J Natl Cancer Inst 1992; 84: 15721575.
  • 41
    Muller AD, Sonnenberg A. Prevention of colorectal cancer by flexible endoscopy and polypectomy. A case-control study of 32,702 veterans. Ann Intern Med 1995; 123: 904910.
  • 42
    Kavanagh AM, Giovannucci EL, Fuchs CS, Colditz GA. Screening endoscopy and risk of colorectal cancer in United States men. Cancer Causes Control 1998; 9: 455462.
  • 43
    Kramer BS, Brown ML, Prorok PC, et al. Prostate cancer screening: what we know and what we need to know. Ann Intern Med 1993; 119: 914923.
  • 44
    Atkin WS. Flexible sigmoidoscopy as a mass screening tool. Eur J Gastroenterol Hepatol 1998; 10: 219223.
  • 45
    Winawer SJ, Flehinger BJ, Schottenfeld D, Miller DG. Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy. J Natl Cancer Inst 1993; 85: 13111318.
  • 46
    Winawer S, Zauber A, Gerdes H, et al. Risk of colorectal cancer in the families of patients with adenomatous polyps: National Polyp Study Workgroup. N Engl J Med 1996; 334: 8287.
  • 47
    Burt RW. Colon cancer screening. Gastroenterology 2000; 119: 837853.
  • 48
    Guillem JG, Puig-La Calle J, Jr., Cellini C, et al. Varying features of early age-of-onset “sporadic” and hereditary nonpolyposis colorectal cancer patients. Dis Colon Rectum 1999; 42: 3642.
  • 49
    U.S. Preventive Services Task Force. Guide to Clinical Preventive Services. 2nd Edition. Washington, DC, U.S. Department of Heath and Human Services, 1996.
  • 50
    Kronborg O, Fenger C, Olsen J, et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996; 348: 14671471.
  • 51
    Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996; 348: 14721477.
  • 52
    Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 1999; 91: 434437.
  • 53
    Lang C, Ransohoff D. Fecal occult blood screening for colorectal cancer: Is mortality reduced by chance selection for screening colonoscopy? JAMA1994; 271: 10111013.
  • 54
    Ederer F, Church TR, Mandel JS. Fecal occult blood screening in the Minnesota study: role of chance detection of lesions. J Natl Cancer Inst 1997; 89: 14231428.
  • 55
    Centers for Disease Control. Screening for colorectal cancer — United States, 1997. Morb Mortal Wkly Rep 1999; 48: 116121.
  • 56
    American Cancer Society. Summary report to the American Cancer Society: Colorectal cancer screening teleconferences with managed care medical directors. Atlanta, American Cancer Society, 1998.
  • 57
    Batelle Corporation. Evaluation of physicians' knowledge, attitudes, and practices related to screening for colorectal cancer. Atlanta, American Cancer Society, 1998.
  • 58
    Malin JL, Kahn K, Dulai G, et al. Organizational systems used by California capitated medical groups and independent practice associations to increase cancer screening. Cancer 2000; 88: 28242831.
  • 59
    American College of Physicians. Suggested technique for fecal occult blood testing and interpretation in colorectal cancer screening. Ann Intern Med 1997; 126: 808810.
  • 60
    Winawer SJ, Stewart ET, Zauber AG, et al. A comparison of colonoscopy and double-contrast barium enema for surveillance after polypectomy. National Polyp Study Work Group. N Engl J Med 2000; 342: 17661772.
  • 60a
    Pignone M, Harris R, Kinsinger L. Videotape-based decision aid for colon cancer screening. A randomized, controlled trial. Ann Intern Med 2000; 133: 761769.
  • 61
    Vernon SW. Participation in colorectal cancer screening: a review. J Natl Cancer Inst 1997; 89: 14061422.
  • 62
    Hara AK, Johnson CD, Reed JE, et al. Detection of colorectal polyps with CT colography: initial assessment of sensitivity and specificity. Radiology 1997; 205: 5965.
  • 63
    Vining DJ. Virtual colonoscopy. Semin Ultrasound CT MR 1999; 20: 5660.
  • 64
    Ahlquist DA. Molecular stool screening for colorectal cancer. Using DNA markers may be beneficial, but large scale evaluation is needed. BMJ 2000; 321: 254255.
  • 65
    Mettlin C. Early detection of prostate cancer following repeated examinations by multiple modalities: results of the American Cancer Society National Prostate Cancer Detection Project. Clin Invest Med 1993; 16: 440447.
  • 66
    Walker JL, Nunez ER. Endometrial cancer, in KramerBS, GohaganJK, ProrokPC (eds): Cancer Screening: Theory And Practice. New York, Marcel Dekker, Inc., 1999, pp 531566.
  • 67
    Cooper JM, Erickson ML. Endometrial sampling techniques in the diagnosis of abnormal uterine bleeding. Obstet Gynecol Clin North Am 2000; 27: 235244.
  • 68
    Gronroos M, Salmi TA, Vuento MH, et al. Mass screening for endometrial cancer directed in risk groups of patients with diabetes and patients with hypertension. Cancer1993; 12791282.
  • 69
    Weigel M, Friese K, Strittmater HJ, Melchert F. Measuring the thickness - is that all we have to do for sonographic assessment of endometrium in postmenopausal women? Ultrasound Obstet Gynecol 1995; 6: 97102.
  • 70
    Gerber B, Krause A, Muller HJ, et al. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: A prospective long-term study using transvaginal ultrasound. J Clin Oncol 2000; 18: 34643470.
  • 71
    Mourits MJ, Van der Zee AG, Willemse PH, et al. Discrepancy between ultrasonography and hysteroscopy and histology of endometrium in postmenopausal breast cancer patients using tamoxifen. Gynecol Oncol 1999; 73: 2126.
  • 72
    Love CD, Muir BB, Scrimgeour JB, et al. Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening. J Clin Oncol 1999; 17: 20502054.
  • 73
    Barakat RR, Gilewski TA, Almadrones L, et al. Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: A prospective study using office endometrial biopsy. J Clin Oncol 2000; 18: 34593463.
  • 74
    Runowicz CD. Gynecologic surveillance of women on tamoxifen: First do no harm. J Clin Oncol 2000; 18: 34573458.
  • 75
    Ng AB, Reagan JW, Hawliczek S, Wentz BW. Significance of endometrial cells in the detection of endometrial carcinoma and its precursors. Acta Cytol 1974; 18: 356361.
  • 76
    Gondos B, King EB. Significance of endometrial cells in cervicovaginal smears. Ann Clin Lab Sci 1977; 7: 486490.
  • 77
    La Vecchia C, Franceschi S, Decarli A, et al. Risk factors for endometrial cancer at different ages. J Natl Cancer Inst 1984; 73: 66771.
  • 78
    Brinton LA, Hoover RN. Estrogen replacement therapy and endometrial cancer risk: unresolved issues. The Endometrial Cancer Collaborative Group. Obstet Gynecol 1993; 81: 265271.
  • 79
    Grady D, Gebretsadik T, Kerlikowske K, et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995; 85: 304313.
  • 80
    Beresford SA, Weiss NS, Voigt LF, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997; 349: 458461.
  • 81
    Persson I, Weiderpass E, Bergkvist L, et al. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control 1999; 10: 253260.
  • 82
    Weiderpass E, Adami HO, Baron JA, et al. Use of oral contraceptives and endometrial cancer risk (Sweden). Cancer Causes Control 1999; 10: 277284.
  • 83
    Rosenblatt KA, Thomas DB. Hormonal content of combined oral contraceptives in relation to the reduced risk of endometrial carcinoma. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Cancer 1991; 49: 870874.
  • 84
    Weiderpass E, Adami HO, Baron JA, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999; 91: 11311137.
  • 85
    Brinton LA, Berman ML, Mortel R, et al. Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study. Am J Obstet Gynecol 1992; 167: 13171325.
  • 86
    McPherson CP, Sellers TA, Potter JD, et al. Reproductive factors and risk of endometrial cancer. The Iowa Women's Health Study. Am J Epidemiol 1996; 143: 11951202.
  • 87
    Pettersson B, Adami HO, Bergstrom R, Johansson ED. Menstruation span—a time-limited risk factor for endometrial carcinoma. Acta Obstet Gynecol Scand 1986; 65: 247255.
  • 88
    Kalandidi A, Tzonou A, Lipworth L, et al. A case-control study of endometrial cancer in relation to reproductive, somatometric, and life-style variables. Oncology 1996; 53: 354359.
  • 89
    Fisher B, Costantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994; 86: 527537.
  • 90
    Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 13711388.
  • 91
    Fornander T, Hellstrom AC, Moberger B. Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J Natl Cancer Inst 1993; 85: 18501855.
  • 92
    Fornander T, Rutqvist LE, Cedermark B, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989; 1: 117120.
  • 93
    Andersson M, Storm HH, Mouridsen HT. Carcinogenic effects of adjuvant tamoxifen treatment and radiotherapy for early breast cancer. Acta Oncol 1992; 31: 259263.
  • 94
    Ribeiro G, Swindell R. The Christie Hospital adjuvant tamoxifen trial. J Natl Cancer Inst Monogr 1992; 11: 121125.
  • 95
    van Leeuwen FE, Benraadt J, Coebergh JW, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994; 343: 448452.
  • 96
    Bernstein L, Deapen D, Cerhan JR, et al. Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 1999; 91: 16541662.
  • 97
    Katase K, Sugiyama Y, Hasumi K, et al. The incidence of subsequent endometrial carcinoma with tamoxifen use in patients with primary breast carcinoma. Cancer 1998; 16981703.
  • 98
    Stewart HJ. The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. Scottish Cancer Trials Breast Group. J Natl Cancer Inst Monogr 1992; 11: 117120.
  • 99
    Lesko SM, Rosenberg L, Kaufman DW, et al. Endometrial cancer and age at last delivery: evidence for an association. Am J Epidemiol 1991; 133: 554559.
  • 100
    Albrektsen G, Heuch I, Tretli S, Kvale G. Is the risk of cancer of the corpus uteri reduced by a recent pregnancy? A prospective study of 765,756 Norwegian women. Int J Cancer 1995; 61: 485490.
  • 101
    Farquhar CM, Lethaby A, Sowter M, et al. An evaluation of risk factors for endometrial hyperplasia in premenopausal women with abnormal menstrual bleeding. Am J Obstet Gynecol 1999; 181: 525529.
  • 102
    Inoue M, Okayama A, Fujita M, et al. A case-control study on risk factors for uterine endometrial cancer in Japan. Jpn J Cancer Res 1994; 85: 346350.
  • 103
    Lambe M, Wuu J, Weiderpass E, Hsieh CC. Childbearing at older age and endometrial cancer risk (Sweden). Cancer Causes Control 1999; 10: 4349.
  • 104
    Lochen ML, Lund E. Childbearing and mortality from cancer of the corpus uteri. Acta Obstet Gynecol Scand 1997; 76: 373377.
  • 105
    Parazzini F, La Vecchia C, Negri E, et al. Reproductive factors and risk of endometrial cancer. Am J Obstet Gynecol 1991; 164: 522527.
  • 106
    Parazzini F, Negri E, La Vecchia C, et al. Role of reproductive factors on the risk of endometrial cancer. Int J Cancer 1998; 76: 784786.
  • 107
    Salazar-Martinez E, Lazcano-Ponce EC, Gonzalez Lira-Lira G, et al. Reproductive factors of ovarian and endometrial cancer risk in a high fertility population in Mexico. Cancer Res 1999; 59: 36583662.
  • 108
    La Vecchia C, Negri E, Francechi S, et al. Long-term impact of reproductive factors on cancer risk. Int J Cancer 1993; 53: 215219.
  • 109
    Brinton LA, Melton LJ 3rd, Malkasian GD, Jr., et al. Cancer risk after evaluation for infertility. Am J Epidemiol 1989; 129: 712722.
  • 110
    Jafari K, Javaheri G, Ruiz G. Endometrial adenocarcinoma and the Stein-Leventhal syndrome. Obstet Gynecol 1978; 51: 97100.
  • 111
    Wood GP, Boronow RC. Endometrial adenocarcinoma and the polycystic ovary syndrome. Am J Obstet Gynecol 1976; 124: 140142.
  • 112
    Cirns JD, Noble AJ, Bryant ME. Carcinoma of endometrium and polycystic ovaries in a 22-year-old patient. Can Med Assoc J 1967; 96: 14731476.
  • 113
    Coulam CB, Annegers JF, Kranz JS. Chronic anovulation syndrome and associated neoplasia. Obstet Gynecol 1983; 61: 403407.
  • 114
    Dahlgren E, Friberg LG, Johansson S, et al. Endometrial carcinoma; ovarian dysfunction—a risk factor in young women. Eur J Obstet Gynecol Reprod Biol 1991; 41(2): 143150.
  • 115
    Austin H, Austin JM, Jr., Partridge EE, et al. Endometrial cancer, obesity, and body fat distribution. Cancer Res 1991; 51: 568572.
  • 116
    Folsom AR, Kaye SA, Potter JD, Prineas RJ. Association of incident carcinoma of the endometrium with body weight and fat distribution in older women: early findings of the Iowa Women's Health Study. Cancer Res 1989; 49: 68286831.
  • 117
    Goodman MT, Hankin JH, Wilkens LR, et al. Diet, body size, physical activity, and the risk of endometrial cancer. Cancer Res 1997; 57: 50775085.
  • 118
    Levi F, La Vecchia C, Negri E, et al. Body mass at different ages and subsequent endometrial cancer risk. Int J Cancer 1992; 50: 567571.
  • 119
    Olson SH, Trevisan M, Marshall JR, et al. Body mass index, weight gain, and risk of endometrial cancer. Nutr Cancer 1995; 23: 141149.
  • 120
    Shoff SM, Newcomb PA. Diabetes, body size, and risk of endometrial cancer. Am J Epidemiol 1998; 148: 234240.
  • 121
    Swanson CA, Potischman N, Wilbanks GD, et al. Relation of endometrial cancer risk to past and contemporary body size and body fat distribution. Cancer Epidemiol Biomarkers Prev 1993; 2: 321327.
  • 122
    Tretli S, Magnus K. Height and weight in relation to uterine corpus cancer morbidity and mortality. A follow-up study of 570,000 women in Norway. Int J Cancer 1990; 46: 165172.
  • 123
    La Vecchia C, Negri E, Franceschi S, et al. A case-control study of diabetes mellitus and cancer risk. Br J Cancer 1994; 70: 950953.
  • 124
    Watson P, Lynch HT. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 1993; 71: 677685.
  • 125
    Watson P, Vasen HF, Mecklin JP, Jarvinen H, Lynch HT. The risk of endometrial cancer in hereditary nonpolyposis colorectal cancer. Am J Med 1994; 96: 516520.
  • 126
    Aarnio M, Mecklin JP, Aaltonen LA, et al. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer 1995; 64: 430433.
  • 127
    Aarnio M, Sankila R, Pukkala E, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999; 81: 214218.
  • 128
    Koss LG. Detection of occult endometrial carcinoma. J Cell Biochem Suppl 1995; 23: 165173.
  • 129
    The periodic health examination. 2. 1987 update. Canadian Task Force on the Periodic Health Examination. CMAJ 1988; 138: 618626.
  • 130
    U.S. Preventive Services Task Force. Guide to Clinical Preventive Services, ed 2. U.S. Department of Health and Human Services, Washington, DC, 1996.
  • 131
    Kim YB, Ghosh K, Ainbinder S, Berek JS. Diagnostic and therapeutic advances in gynecologic oncology: screening for gynecologic cancer. Cancer Treat Res 1998; 95: 253276.
  • 132
    Burke W, Petersen G, Lynch P, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium. JAMA 1997; 277: 915919.
  • 133
    Offit K. Clinical Cancer Genetics. New York, John Wiley and Sons, 1998.
  • 134
    Lynch HT, Smyrk T. Hereditary nonpolyposis colorectal cancer (Lynch syndrome). An updated review. Cancer 1996; 78: 11491167.
  • 135
    Suzuki K, Nagai K, Yoshida J, et al. Prognostic factors in clinical stage I non-small cell lung cancer. Ann Thorac Surg 1999; 67: 927932.
  • 136
    Martini N. Mediastinal lymph node dissection for lung cancer. The Memorial experience. Chest Surg Clin N Am 1995; 5: 189203.
  • 137
    Hankey BF. Personal communication, 2000.
  • 138
    Patz Jr E, Rossi S, Harpole D Jr, et al. Correlation of tumor size and survival in patients with stage IA non-small cell lung cancer. Chest 2000; 117: 15681571.
  • 139
    Black WC. Lung cancer, in KramerBS, GohaganJK, ProrokPC (eds): Cancer Screening: Theory and Practice. New York, Marcel Dekker, Inc., 1999, pp 327377.
  • 140
    American Cancer Society. Cancer Risk Report: Prevention and Control, 1999. Atlanta, American Cancer Society, 1999.
  • 141
    Centers for Disease Control. Youth tobacco surveillance, 1998–1999. Morb Mortal Wkly Rep - Surveill Summ 2000; 49(SS10): 193.
  • 142
    Peto R, Darby S, Deo H, et al. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ 2000; 321: 323329.
  • 143
    Fontana RS: The Mayo Lung Project: A perspective. Presented at the International Conference on Prevention and Early Diagnosis of Lung Cancer Varese, Italy, 1998:1520.
  • 144
    Fontana RS, Sanderson DR, Woolner LB, et al. Screening for lung cancer. A critique of the Mayo Lung Project. Cancer 1991; 67(4 Suppl): 11551164.
  • 145
    Strauss GM, Dominioni L. Lung cancer screening and the surgical oncologist: the controversy. Surg Oncol Clin N Am 1999; 8: 371387.
  • 146
    Muhm JR, Miller WE, Fontana RS, et al. Lung cancer detected during a screening program using four-month chest radiographs. Radiology 1983; 148: 609615.
  • 147
    Henschke CI, McCauley DI, Yankelevitz DF, et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 1999; 354: 99105.
  • 148
    Petty TL. The early identification of lung cancer by sputum cytology. Cancer 2000; 89(11 suppl): 24612464.
  • 149
    Hittelman WH. Molecular risk assessment in current and former cigarette smokers, in Dominioni L, Strauss G (eds): International Conference on Prevention and Early Diagnosis of Lung Cancer, Varese, Italy, 1998, pp 117120.
  • 150
    American Cancer Society. The American Cancer Society Guideline for the cancer-related checkup: an update. Atlanta, American Cancer Society, 1993.
  • 151
    American Academy of Family Physicians. Age charts for the periodic health examination. Based on the American Academy of Family Physicians Summary of Policy Recommen-dations for Periodic Health Examinations, November 1996; Revision 4.0, July 2000.
  • 152
    Eddy DM. Screening for lung cancer, in EddyDM (ed): Common Screening Tests. Philadelphia, American College of Physicians, 1991, pp 312325.
  • 153
    Smith RA, Glynn TJ. Early lung cancer detection. Cancer 2000; 89(11 suppl): 23272329.
  • 154
    Strauss G, Dominioni L. Varese meeting report. Lung Cancer 1999; 23: 171172.
  • 155
    Marcus PM, Prorok PC. Reanalysis of the Mayo Lung Project data: the impact of confounding and effect modification. J Med Screen 1999; 6: 4749.
  • 156
    Weed D. Ethics and consent, in KramerBS, GohaganJK, ProrokPC (eds): Cancer Screening: Theory and Practice. New York, Marcel Dekker, Inc., 1999, pp 89140.
  • 157
    Surveillance Implementation Group. Cancer Surveillance Research Implementation Plan. Bethesda, MD, National Cancer Institute, 1999.
  • 158
    CDC Behavioral Surveillance Branch. 1999 Behavioral Risk Factor Surveillance System Summary Prevalence Report. Atlanta, GA, Centers for Disease Control, 2000.
  • 159
    Holtzman D, Powell-Griner E, Bolen J, Rhodes L. State- and Sex-Specific Prevalence of Selected Characteristics — Behavioral Risk Factor Surveillance System, 1996 and 1997. Morb Mortal Wkly Rep - Surveill Summ 2000; 49(SS06): 139.
  • 160
    Bolen J, Rhodes L, Powell-Griner E, et al. State-Specific Prevalence of Selected Health Behaviors, by Race and Ethnicity — Behavioral Risk Factor Surveillance System, 1997. Morb Mortal Wkly Rep - Surveill Summ 2000; 49(SS02): 160.
  • 161
    Bindman AB, Grumbach K, Osmond D, et al. Primary care and receipt of preventive services. J Gen Intern Med 1996; 11: 269276.
  • 162
    Gulitz E, Bustillo-Hernandez M, Kent E. Missed cancer screening opportunities among older women: A provider survey. Cancer Practice. 1998; 6: 325332.
  • 163
    Blackman DK, Bennett EM, Miller DS. Trends in self-reported use of mammograms (1989–1997) and Papanicolaou tests (1991–1997) — Behavioral Risk Factor Surveillance System. Morb Mortal Wkly Rep - Surveill Summ 1999; 48(SS06): 122.
  • 164
    Steele C, Miller D, Maylahn C, Uhler R, Baker C. Knowledge, attitudes, and screening practices among older men regarding prostate cancer. Am J Public Health 2000; 90: 15951600.
  • 165
    Marks J, Lee N. Implementing recommendations for the early detection of breast and cervical cancer among low-income women. Morbidity and Mortality Weekly Reports - Recomm Rep 2000; 49(RR02): 3555.
  • 166
    Centers for Disease Control. Update: National breast and cervical cancer early detection program - July 1991-September 1995. Morb Mortal Wkly Rep 1996; 45: 484487.
  • 167
    Hoffman-Goetz L, Mills S. Cultural barriers to cancer screening among African American women: a critical review of the qualitative literature. Womens Health 1997; 3: 183201.
  • 168
    Lane D, Caplan L, Grimson R. Trends in mammography use and their relation to physician and other factors. Cancer Detection and Prevention 1996; 20: 332341.
  • 169
    Hawley S, Earp J, O'Malley M, Ricketts T. The role of physician recommendation in women's mammography use: is it a 2-stage process? Medical Care 2000; 38: 392403.
  • 170
    Horton JA, Romans MC, Cruess DF. Mammography attitudes and usage study, 1992. Womens Health Issues1992; 2: 180186;discussion 187–188.
  • 171
    Smith RA, Haynes S. Barriers to screening for breast cancer. Cancer 1992; 69(7 Suppl): 19681978.
  • 172
    Rimer BK, Trock B, Engstrom PF, et al. Why do some women get regular mammograms? Am J Prev Med 1991; 7: 6974.
  • 173
    Screening mammography. a missed clinical opportunity? Results of the NCI Breast Cancer Screening Consortium and National Health Interview Survey Studies. National Cancer Institute Breast Cancer Screening Consortium. JAMA 1990; 264: 5458.
  • 174
    Kiefe CI, Funkhouser E, Fouad MN, May DS. Chronic disease as a barrier to breast and cervical cancer screening. J Gen Intern Med 1998; 13: 357365.
  • 175
    Rimer BK. Current use and how to increase mammography screening in women. Surg Oncol Clin N Am 1997; 6: 203211.
  • 176
    Dietrich JJ, O'Conner GT, Keller A, Carney PA, Levy D, Whaley FS. Cancer: improving early detection and prevention. A community practice randomised trial. BMJ 1992; 304: 687691.
  • 177
    Dietrich JJ, Woodruff CB, Carney PA. Changing office routines to enhance preventive care. The preventive GAPS approach. Arch Fam Med 1994; 3: 176183.
  • 178
    Gann P, Melville SK, Luckmann R. Characteristics of primary care office systems as predictors of mammography utilization. Ann Intern Med 1993; 118: 893898.
  • 179
    Garr DR, Ornstein SM, Jenkins RG, Zemp LD. The effect of routine use of computer-generated preventive reminders in a clinical practice. Am J Prev Med 1993; 9: 5561.
  • 180
    McPhee SJ, Bird JA, Jenkins CN, Fordham D. Promoting cancer screening. A randomized, controlled trial of three interventions. Arch Intern Med 1989; 149: 18661872.
  • 181
    McPhee SJ, Bird JA, Fordham D, et al. Promoting cancer prevention activities by primary care physicians. Results of a randomized, controlled trial. JAMA1991; 266: 538544.